Expression of ATAD2 in different liver lesions and its clinical significance
10.3760/cma.j.issn.1007-3418.2017.05.006
- VernacularTitle: 三磷酸腺苷酶家族蛋白2在不同病变肝组织中的表达意义及临床应用探讨
- Author:
Fen LIU
1
;
Xuan ZHOU
2
;
Huihui JI
1
;
Hong LI
2
;
Fenggang XIANG
1
,
3
Author Information
1. Department of Pathology, Qingdao University Basic Medicine College, Qingdao 266021, China
2. Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266003, Chian
3. Department of Pathology, the Affiliated Hospital of Qingdao University, Qingdao 266003, Chian
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Tumorigenesis;
Diagnosis;
ATAD2
- From:
Chinese Journal of Hepatology
2017;25(5):339-343
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To examine the expression of ATAD2 in different liver lesions and its clinical significance.
Methods:ATAD2 expression in 60 hepatocellular carcinoma (HCC) surgical specimens (49 of which have concurrent liver cirrhosis), 43 HCC biopsy specimens, 2 high-grade liver dysplastic nodule specimens, 3 low-grade liver dysplastic nodule specimens, 50 liver cirrhosis tissue samples, and 20 normal liver tissue samples were measured using immunohistochemistry. The F-test, q-test, t-test, and chi-square test were used for statistical analysis of data.
Results:ATAD2 was expressed in 56 HCC surgical specimens (93.33%), 35 HCC biopsy specimens (81.40%), and 2 high-grade liver dysplastic nodule specimens (2/2), but not in the low-grade liver dysplastic nodule, liver cirrhosis tissue, and normal liver tissue samples. The mean expression of ATAD2 was significantly higher in HCC tissues than in high-grade and low-grade liver dysplastic nodule tissues, liver cirrhosis tissue, and normal liver tissue (F = 22.96, q = 3.138, 3.972, 12.272, and 9.101, respectively, all P < 0.01). There were no significant differences in the mean expression and positive expression rate of ATAD2 between HCC surgical and biopsy specimens (t = 1.40, P > 0.05; χ² = 3.47, P >0.05). Of the 35 HCC biopsy specimens that expressed ATAD2, the mean ATAD2 expression was ≥1% in 35 specimens (100%), ≥3% in 27 specimens (77.14%), and ≥5 % in 23 specimens (65.71%). In addition, among the pathological grade I-II HCC biopsy specimens, the mean ATAD2 expression was ≥1% in 28 specimens (100%), ≥3% in 22 specimens (62.86%), and ≥5% in 19 specimens (54.29%). Moreover, ATAD2 expression in HCC was associated with serum alpha-fetoprotein level, presence of hepatitis B virus surface antigen (HBsAg), and presence of concurrent liver cirrhosis (t = 2.09, 2.30, and 2.18, respectively, all P < 0.05).
Conclusion:ATAD2 may play an important role in HCC tumorigenesis, and may be involved in malignant transformation of cells. ATAD2 expression can be a valuable marker for differentiating the nature of lesions in liver biopsy tissues during clinical practice.
